Cardiac Troponin Market: Current Analysis and Forecast (2023-2030)

The Cardiac troponin market is expected to register a CAGR of approx. 10.2% over the period of 2023-2030. Cardiac troponins are proteins released into the bloodstream when the heart muscle is damaged, making them essential markers for diagnosing heart attacks and other cardiac conditions. The prevalence of cardiovascular diseases, such as heart attacks, heart failure, and myocardial infarctions, is a significant driver of the cardiac troponin market. As these conditions continue to affect a large portion of the population globally, the demand for troponin testing to diagnose and monitor these diseases remains high. For instance, in 2024, There are around 620 million people living with heart and circulatory diseases across the world. Globally it's estimated that 1 in 13 people are living with a heart or circulatory disease. Furthermore, advances in technology have led to the development of more sensitive and specific troponin assays. These advancements improve the accuracy and reliability of troponin testing, driving adoption in clinical practice. Additionally, the aging population is more susceptible to cardiovascular diseases, leading to a higher demand for cardiac biomarker testing, including troponin..

Based on setting, the market is segmented into Laboratory Testing, Point-of-Care (POC) Testing. The laboratory testing therapy category is expected to witness the highest CAGR during the forecast period. Laboratory-based troponin assays typically offer high accuracy and precision, making them well-suited for the diagnosis and monitoring of cardiovascular diseases. Healthcare providers often rely on laboratory testing to obtain precise troponin measurements, especially in cases requiring serial testing or when assessing patients with complex medical conditions. For instance, In 2021, ARCHITECT hsTnI I 20 assay. This high-sensitivity troponin I assay boasts improved precision and sensitivity for accurate heart attack diagnosis and exclusion. Additionally, Laboratory-based testing platforms offer comprehensive capabilities for cardiac biomarker testing, including troponin assays, alongside other relevant tests such as lipid profiles, electrolyte panels, and cardiac imaging..

Based on indication, the cardiac troponin market has been classified as myocardial infarction, acute coronary syndrome, coronary heart disease, congestive heart failure, and others. Among them, the myocardial infarction segment is expected to grow at a higher share in the market. Despite advancements in preventive cardiology and cardiovascular care, heart attacks remain a leading cause of morbidity and mortality globally. The aging population, rising prevalence of cardiovascular risk factors, such as hypertension, diabetes, and obesity, and lifestyle changes contribute to the increasing incidence of heart attacks, driving demand for troponin testing in the diagnosis and management of acute myocardial infarction.

Based on the end-user, the cardiac troponin market has been classified into hospitals, diagnostic centers, others. Among them, the hospitals category is to witness higher adoption of Cardiac Troponin during the forecast period. : Hospitals are the primary settings for managing patients with acute cardiovascular conditions, such as myocardial infarction and heart failure. The rising incidence of these conditions, coupled with population aging and the increasing prevalence of cardiovascular risk factors, leads to higher patient admissions to hospitals, driving demand for troponin testing in these settings. Moreover, Hospitals implement standardized clinical pathways and protocols for the evaluation and management of acute cardiovascular conditions, incorporating troponin testing into routine practice. Adherence to evidence-based guidelines ensures consistent and optimal use of troponin testing, supporting timely diagnosis, risk stratification, and treatment initiation.

For a better understanding of the market adoption of the Cardiac troponin industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America cardiac troponin market is expected to continue to grow in the coming years, driven by the increasing prevalence of cardiovascular disease and growing awareness of cardiac troponin among healthcare professionals and the general population, development of advanced techniques and the rise in treatment option. For instance, in 2019, according to CDC, Every year, about 805,000 people in the United States have a heart attack. About 1 in 5 heart attacks are silent, the damage is done, but the person is not aware of it.

Some of the major players operating in the market include F. Hoffmann-La Roche Ltd., BIOMERIEUX., Abbott, Siemens Healthcare Private Limited, Beckman Coulter, Inc, Trinity Biotech, Bio-Techne, PerkinElmer Inc, Bio-Rad Laboratories, Inc, Eurolyser Diagnostica GmbH.